格隆汇1月30日丨上海莱士(002252.SZ)公布，全资子公司同路生物制药有限公司（"同路生物"）于近期 收到国家药品监督管理局签发的《药品注册证书》，药品名称：人纤维蛋白原。人纤维蛋白原系由健康 人血浆，经分离、提纯，并经病毒去除和灭活处理、冻干制成。同路生物本产品适应症为先天性纤维蛋 白原减少或缺乏症。 ...

药品名称：人纤维蛋白原； 剂型：注射剂； 注册分类：治疗用生物制品； 规格：0.5g/瓶； 证券代码：002252 证券简称：上海莱士 公告编号：2026-001 上海莱士血液制品股份有限公司 关于全资子公司获得《药品注册证书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）全资子公司同路生物制药有限公 司（"同路生物"）于近期收到国家药品监督管理局签发的《药品注册证书》，具 体情况如下： 一、药品注册证书主要内容 人纤维蛋白原系由健康人血浆，经分离、提纯，并经病毒去除和灭活处理、 冻干制成。同路生物本产品适应症为先天性纤维蛋白原减少或缺乏症。 三、对公司的影响及风险提示 本次同路生物获得人纤维蛋白原《药品注册证书》，进一步丰富了公司的产 1 品布局，提高公司血浆的综合利用率，有利于增强公司的核心竞争力和市场地位。 同路生物将加快推进该产品的相关生产安排，积极促使其早日上市。 药品注册标准编号：YBS00012026； 药品批准文号：国药准字 S20260007； 上市许可持有人：同路生物制药有限公司； 生产企业 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.3% on January 29, with Hualan Vaccine leading the drop [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Individual Stock Performance - Weigao Bio (002880) saw a closing price of 30.07, with an increase of 4.59% and a trading volume of 88,100 shares, totaling a transaction value of 266 million yuan [1] - Changchun High-tech (000661) closed at 98.30, up 0.92%, with a trading volume of 64,700 shares and a transaction value of 629 million yuan [1] - Other notable performers include Boya Bio (300294) and Zhifei Biological (300122), both with a closing price increase of 0.92% and 0.73% respectively [1] Declining Stocks - Hualan Bio (301207) reported a significant decline of 9.05%, closing at 22.62, with a trading volume of 300,600 shares and a transaction value of 689 million yuan [2] - Junshi Biosciences (688180) fell by 6.02%, closing at 36.82, with a trading volume of 266,100 shares and a transaction value of 1 billion yuan [2] - Other stocks such as Jinkang (688670) and Bohui Innovation (300318) also experienced declines of 5.81% and 4.95% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 866 million yuan from institutional investors, while retail investors contributed a net inflow of 682 million yuan [2] - Notable net inflows from retail investors were observed in stocks like Shanghai Laishi (002252) and Weigao Bio (002880) [3] - Conversely, stocks such as Zhixiang Quantai (688443) and Weigao Bio (002880) experienced significant net outflows from institutional and speculative investors [3]

Group 1 - The company Shanghai Laishi (002252) stated that it currently has no products for Nipah virus testing [1] - The company also mentioned that there is no collaboration with Shanghai Institute of Pharmaceutical Industry at this time [1]

Group 1 - The company Shanghai Laishi (002252.SZ) has stated that it currently does not have any products for Nipah virus testing [1] - There is no collaboration with Shanghai Institute of Pharmaceutical Industry at this time [1]

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

会上，2025年奉贤区"揭榜挂帅"合作项目签约，莱士血液、自然堂、如昂超声波等区内重点企业与复旦 大学、上海交通大学等高校达成多项合作。中国科学院上海高等研究院、上海交通大学、毅达资本等10 家机构成为"南上海科创中心生态合作伙伴"，一批来自高校、产业与投资领域的专家成为"南上海科创 人才创业导师"，为区域创新提供智力与资源支撑。 上海市研发公共服务平台管理中心、创业邦与奉贤区科委、上海市城市设计与城市科学重点实验室分别 与东方美谷集团签订合作协议，共同构建资源共享、服务联动的创新支撑体系。 现场还发布了奉贤区科技政策包，政策涵盖企业培育、成果转化、人才引育等多方面内容，为科技企业 发展、科技创新突破提供政策保障。 （文章来源：新华财经） 新华财经上海1月26日电（记者李荣）上海奉贤大力推动科技创新与产业创新的深度融合，聚力打造"热 带雨林式"创新生态体系，以高水平科技创新引领新质生产力发展。记者26日从2026南上海科创大会上 获悉，奉贤正与各方携手共建南上海科创中心。 上海市科学技术委员会相关人士介绍，上海正全力推进国际科技创新中心建设从"建框架"向"强功能"跨 越，奉贤作为上海南部重要战略空间和增长极， ...

Group 1 - The company, Shanghai Laishi, is considering the feasibility and rationality of a potential share buyback plan based on its current operating cash flow, daily production and operational funding needs, and research and development investments [1] - The company will fulfill its announcement obligations in accordance with information disclosure rules if it decides to implement a buyback plan in the future [1]

证券之星消息，1月23日生物制品板块较上一交易日上涨1.45%，沃森生物领涨。当日上证指数报收于 4136.16，上涨0.33%。深证成指报收于14439.66，上涨0.79%。生物制品板块个股涨跌见下表： 从资金流向上来看，当日生物制品板块主力资金净流入1.98亿元，游资资金净流出2.72亿元，散户资金净 流入7437.55万元。生物制品板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300142 沃森生物 | | 1.34 Z | 9.80% | -8331.39万 | -6.11% | -5032.70万 | -3.69% | | 000661 | 长春高新 | 5154.65万 | 8.00% | -1654.92万 | -2.57% | -3499.73万 | -5.43% | | 002252 上海莱士 | | 4593.03万 | 13.12% | -2426.69万 | - ...

（编辑 丛可心） 证券日报网讯 1月22日，上海莱士在互动平台回答投资者提问时表示，按照相关规则，权益分派事项应 当在上市公司股东会审议通过利润分配方案后两个月内完成。公司于2025年12月15日召开的2025年第三 次临时股东会，会上审议通过了《2025年前三季度利润分配方案》，公司将按照前述规则要求及时完成 权益分派事项，具体分派时间以公司公告为准。 ...